European Neuropsychopharmacology最新文献

英文中文

Single-cell atlas of schizophrenia peripheral immunity implicates neutrophil-driven inflammation and adaptive immune suppression 精神分裂症外周免疫的单细胞图谱涉及中性粒细胞驱动的炎症和适应性免疫抑制

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-11-01 Epub Date: 2025-09-22 DOI: 10.1016/j.euroneuro.2025.09.001

Ying Jiang, Lu Hou, Shiming Li, Zhiqiang Du, Rongrong Lu, Xuezheng Gao, Haohao Zhu

引用次数: 0

Reply from the Authors 作者的答复

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-11-01 Epub Date: 2025-09-22 DOI: 10.1016/j.euroneuro.2025.09.005

Elisabet Jerlhag

引用次数: 0

Reply to Jianjie Ju and Hui Chen 回复鞠建杰和陈辉

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-11-01 Epub Date: 2025-09-22 DOI: 10.1016/j.euroneuro.2025.09.003

Alessandro Serretti

引用次数: 0

Structural connectomic signatures of childhood maltreatment across affective and psychotic disorders 儿童期虐待在情感性和精神性障碍中的结构连接组特征。

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-11-01 Epub Date: 2025-10-13 DOI: 10.1016/j.euroneuro.2025.09.009

Linda M. Bonnekoh , Marius Gruber , Cathrine Thams , Kira Flinkenflügel , Susanne Meinert , Janik Goltermann , Dominik Grotegerd , Julia Hubbert , Judith Krieger , Christoph Jurischka , Ruth H. Fellmeth , Nils R. Winter , Tim Hahn , Elisabeth J. Leehr , Nils Opel , Marc Pawlitzki , Paula Rehm , Nina v. Werthern , Sharmili Edwin Thanarajah , Stefanie Fischer , Jonathan Repple

Exposure to childhood maltreatment (CM) is a crucial risk factor for affective disorders and schizophrenia, which are linked to structural brain network alterations. We hypothesized a significant association between CM and brain structural connectivity in a transdiagnostic sample. Participants included patients with major depressive disorder (n = 827), bipolar disorder (n = 134), schizophrenia spectrum disorders (n = 118), and healthy controls (n = 932) aged 18–65 from the Marburg-Muenster Affective Disorders Cohort Study. Structural brain networks were reconstructed from structural and diffusion-weighted MRI. CM was assessed using the Childhood Trauma Questionnaire (CTQ) based on established cut-offs. Analyses of covariance investigated the main effect of CM and the interaction of diagnosis and CM on global network metrics. In addition, network-based statistic (NBS) analyses were performed to identify the underlying subnetworks. History of CM was positively associated with the number of connections (p_FDR=0.01; CM: 95 %-CI=[533.9; 540.6], No CM: 95 %-CI=[529.1; 535.0]), normalized (p_FDR=0.02; CM: 95 %-CI=[0.860; 0.863], No CM: 95 %-CI=[0.857; 0.860]) and non-normalized network efficiency (p_FDR=0.01; CM: 95 %-CI=[0.405; 0.407], No CM: 95 %-CI=[0.403; 0.405]) and negatively associated with normalized network clustering (p_FDR=0.045; CM: 95 %-CI=[4.976; 5.065], No CM: 95 %-CI=[5.100; 5.150]). There were no significant interaction effects of CM and diagnosis. NBS analyses revealed a large network of edges, in which individuals with CM exhibited higher structural connectivity compared to those without, which persisted after correcting for diagnosis. These findings indicate a connectome signature of CM, marked by hyperconnectivity, across major mental disorders and in healthy individuals, suggesting that CM affects connectome architecture independent of present psychiatric diagnoses.

暴露于儿童虐待（CM）是情感障碍和精神分裂症的关键风险因素，这与大脑结构网络改变有关。我们假设在跨诊断样本中CM和脑结构连接之间存在显著关联。参与者包括来自Marburg-Muenster情感障碍队列研究的18-65岁的重度抑郁症（n = 827）、双相情感障碍（n = 134）、精神分裂症谱系障碍（n = 118）和健康对照（n = 932）患者。通过结构和弥散加权MRI重建脑结构网络。CM评估使用儿童创伤问卷（CTQ）基于既定的切断。协方差分析研究了CM的主要作用以及诊断和CM对全局网络指标的交互作用。此外，还进行了基于网络的统计（NBS）分析，以确定底层子网。CM病史与连接数（pFDR=0.01, CM: 95% -CI=[533.9; 540.6], No CM: 95% -CI=[529.1; 535.0]）、归一化（pFDR=0.02, CM: 95% -CI=[0.860; 0.863], No CM: 95% -CI=[0.857; 0.860]）和非归一化网络效率（pFDR=0.01, CM: 95% -CI=[0.405; 0.407], No CM: 95% -CI=[0.403; 0.405]）呈正相关，与归一化网络聚类（pFDR=0.045, CM: 95% -CI=[4.976; 5.065], No CM: 95% -CI=[5.100; 5.150]）呈负相关。CM与诊断无显著交互作用。NBS分析揭示了一个巨大的边缘网络，与没有CM的个体相比，CM个体表现出更高的结构连通性，这种连通性在纠正诊断后仍然存在。这些发现表明，在主要精神障碍和健康个体中，CM的连接组特征以超连通性为特征，表明CM影响连接组结构独立于目前的精神病学诊断。

{"title":"Structural connectomic signatures of childhood maltreatment across affective and psychotic disorders","authors":"Linda M. Bonnekoh , Marius Gruber , Cathrine Thams , Kira Flinkenflügel , Susanne Meinert , Janik Goltermann , Dominik Grotegerd , Julia Hubbert , Judith Krieger , Christoph Jurischka , Ruth H. Fellmeth , Nils R. Winter , Tim Hahn , Elisabeth J. Leehr , Nils Opel , Marc Pawlitzki , Paula Rehm , Nina v. Werthern , Sharmili Edwin Thanarajah , Stefanie Fischer , Jonathan Repple","doi":"10.1016/j.euroneuro.2025.09.009","DOIUrl":"10.1016/j.euroneuro.2025.09.009","url":null,"abstract":"<div><div>Exposure to childhood maltreatment (CM) is a crucial risk factor for affective disorders and schizophrenia, which are linked to structural brain network alterations. We hypothesized a significant association between CM and brain structural connectivity in a transdiagnostic sample. Participants included patients with major depressive disorder (<em>n</em> = 827), bipolar disorder (<em>n</em> = 134), schizophrenia spectrum disorders (<em>n</em> = 118), and healthy controls (<em>n</em> = 932) aged 18–65 from the Marburg-Muenster Affective Disorders Cohort Study. Structural brain networks were reconstructed from structural and diffusion-weighted MRI. CM was assessed using the Childhood Trauma Questionnaire (CTQ) based on established cut-offs. Analyses of covariance investigated the main effect of CM and the interaction of diagnosis and CM on global network metrics. In addition, network-based statistic (NBS) analyses were performed to identify the underlying subnetworks. History of CM was positively associated with the number of connections (p<sub>FDR</sub>=0.01; CM: 95 %-CI=[533.9; 540.6], No CM: 95 %-CI=[529.1; 535.0]), normalized (p<sub>FDR</sub>=0.02; CM: 95 %-CI=[0.860; 0.863], No CM: 95 %-CI=[0.857; 0.860]) and non-normalized network efficiency (p<sub>FDR</sub>=0.01; CM: 95 %-CI=[0.405; 0.407], No CM: 95 %-CI=[0.403; 0.405]) and negatively associated with normalized network clustering (p<sub>FDR</sub>=0.045; CM: 95 %-CI=[4.976; 5.065], No CM: 95 %-CI=[5.100; 5.150]). There were no significant interaction effects of CM and diagnosis. NBS analyses revealed a large network of edges, in which individuals with CM exhibited higher structural connectivity compared to those without, which persisted after correcting for diagnosis. These findings indicate a connectome signature of CM, marked by hyperconnectivity, across major mental disorders and in healthy individuals, suggesting that CM affects connectome architecture independent of present psychiatric diagnoses.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"100 ","pages":"Pages 42-52"},"PeriodicalIF":6.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145291538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to the letter to the editor: “Compressed design, inflated conclusions? A cautionary note on vaporized DMT trials” 回复给编辑的信：“压缩的设计，夸大的结论？关于汽化DMT试验的警告

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-11-01 Epub Date: 2025-09-23 DOI: 10.1016/j.euroneuro.2025.09.008

Fernanda Palhano-Fontes

引用次数: 0

Comment on “Comparative receptor pharmacology of antipsychotic drugs based on normalized binding affinity data and breadth of interaction” 评《基于归一化结合亲和力数据和相互作用广度的抗精神病药物比较受体药理学》

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-11-01 Epub Date: 2025-09-22 DOI: 10.1016/j.euroneuro.2025.09.002

Parth Aphale, Shashank Dokania, Himanshu Shekhar

引用次数: 0

Methodological gaps in treatment-resistant depression prediction 难治性抑郁症预测的方法学空白

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-11-01 Epub Date: 2025-09-05 DOI: 10.1016/j.euroneuro.2025.08.578

Hui Chen

引用次数: 0

Antipsychotic polypharmacy in patients with schizophrenia between 1999 and 2024 in Denmark: Prevalence, time trends, and combinations 1999年至2024年间丹麦精神分裂症患者的抗精神病药物：患病率，时间趋势和组合

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-11-01 Epub Date: 2025-08-28 DOI: 10.1016/j.euroneuro.2025.08.580

Mikkel Højlund , Christopher Rohde , Christiane Gasse , Jesper Hallas , Anders Fink-Jensen , Christoph U. Correll , Ole Köhler-Forsberg

Antipsychotic polypharmacy (APP) remains common in the treatment of schizophrenia despite increased risk of adverse events and limited evidence of additional efficacy compared to antipsychotic monotherapy (APM). We conducted a nationwide, register-based cohort study to characterize APP among patients with schizophrenia in Denmark, 1997–2021. Patients were followed from year 3 after the schizophrenia diagnosis and onwards. APP was defined as treatment with ≥2 antipsychotics lasting ≥60 days. Of 29,696 patients with schizophrenia (55 % males; median age 29 years [interquartile range (IQR) = 22–41 years]; median follow-up 10.5 years [IQR 5.1–16.3]), 51 % of patients were exposed to APP at some point during follow-up. The one-year prevalence of APP decreased from 44 % in 2005 to 29 % in 2024. In 2024, 58 % of APP regimens involved quetiapine, and 52 % involved clozapine and/or partial dopamine receptor agonists. Median total dose of antipsychotics was significantly higher with APP than with APM (1.4 vs. 0.7 WHO-defined daily doses;p < 0.001). In 2024, 43 % of APP included chlorprothixene or quetiapine (≤100mg/day). Use of APP was associated with male sex, more and longer hospitalizations, suicide attempts/self-harm, alcohol/substance use, use of antidepressants, mood stabilizers, hypnotics, or benzodiazepines (all p < 0.001). Although the prevalence of APP in schizophrenia decreased from 2005 to 2024, one-third of patients with schizophrenia remained exposed to APP. Only half of APP included potentially evidence-based combinations with clozapine and/or partial dopamine-receptor agonists. APP was associated with higher total antipsychotic doses, but also with more severe schizophrenia illness. These findings can inform future studies to investigate the comparative efficacy and safety of specific APP combinations and potential opportunities for deprescribing APP.

抗精神病药物综合治疗（APP）在精神分裂症的治疗中仍然很常见，尽管与抗精神病药物单一治疗（APM）相比，不良事件的风险增加，并且证据有限。我们进行了一项全国性的、基于登记的队列研究，以表征1997-2021年丹麦精神分裂症患者的APP。从精神分裂症诊断后的第3年开始对患者进行随访。APP定义为服用≥2种抗精神病药物持续≥60天。29,696例精神分裂症患者(55%为男性，中位年龄29岁[四分位数间距(IQR) = 22-41岁]；中位随访10.5年[IQR 5.1-16.3])， 51%的患者在随访期间的某个时间点暴露于APP。APP的一年患病率从2005年的44%下降到2024年的29%。2024年，58%的APP方案使用喹硫平，52%使用氯氮平和/或部分多巴胺受体激动剂。APP组抗精神病药物的中位总剂量显著高于APM组（who定义的每日剂量1.4 vs 0.7;p < 0.001）。2024年，43%的APP含有氯丙噻烯或喹硫平（≤100mg/天）。APP的使用与男性性别、住院次数和住院时间、自杀未遂/自残、酒精/物质使用、使用抗抑郁药、情绪稳定剂、催眠药或苯二氮卓类药物相关（均p <； 0.001）。虽然从2005年到2024年，APP在精神分裂症中的患病率有所下降，但三分之一的精神分裂症患者仍然暴露于APP。只有一半的APP包括氯氮平和/或部分多巴胺受体激动剂的潜在循证联合用药。APP与较高的抗精神病药物总剂量有关，但也与更严重的精神分裂症疾病有关。这些发现可以为未来的研究提供信息，以调查特定APP组合的相对疗效和安全性，以及APP处方的潜在机会。

{"title":"Antipsychotic polypharmacy in patients with schizophrenia between 1999 and 2024 in Denmark: Prevalence, time trends, and combinations","authors":"Mikkel Højlund , Christopher Rohde , Christiane Gasse , Jesper Hallas , Anders Fink-Jensen , Christoph U. Correll , Ole Köhler-Forsberg","doi":"10.1016/j.euroneuro.2025.08.580","DOIUrl":"10.1016/j.euroneuro.2025.08.580","url":null,"abstract":"<div><div>Antipsychotic polypharmacy (APP) remains common in the treatment of schizophrenia despite increased risk of adverse events and limited evidence of additional efficacy compared to antipsychotic monotherapy (APM). We conducted a nationwide, register-based cohort study to characterize APP among patients with schizophrenia in Denmark, 1997–2021. Patients were followed from year 3 after the schizophrenia diagnosis and onwards. APP was defined as treatment with ≥2 antipsychotics lasting ≥60 days. Of 29,696 patients with schizophrenia (55 % males; median age 29 years [interquartile range (IQR) = 22–41 years]; median follow-up 10.5 years [IQR 5.1–16.3]), 51 % of patients were exposed to APP at some point during follow-up. The one-year prevalence of APP decreased from 44 % in 2005 to 29 % in 2024. In 2024, 58 % of APP regimens involved quetiapine, and 52 % involved clozapine and/or partial dopamine receptor agonists. Median total dose of antipsychotics was significantly higher with APP than with APM (1.4 vs. 0.7 WHO-defined daily doses;<em>p</em> < 0.001). In 2024, 43 % of APP included chlorprothixene or quetiapine (≤100mg/day). Use of APP was associated with male sex, more and longer hospitalizations, suicide attempts/self-harm, alcohol/substance use, use of antidepressants, mood stabilizers, hypnotics, or benzodiazepines (all <em>p</em> < 0.001). Although the prevalence of APP in schizophrenia decreased from 2005 to 2024, one-third of patients with schizophrenia remained exposed to APP. Only half of APP included potentially evidence-based combinations with clozapine and/or partial dopamine-receptor agonists. APP was associated with higher total antipsychotic doses, but also with more severe schizophrenia illness. These findings can inform future studies to investigate the comparative efficacy and safety of specific APP combinations and potential opportunities for deprescribing APP.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"100 ","pages":"Pages 4-12"},"PeriodicalIF":6.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144907679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Esketamine in bipolar depression: Are we overlooking critical subgroups and dosing details? 艾氯胺酮治疗双相抑郁症：我们是否忽视了关键亚群和剂量细节？

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-11-01 Epub Date: 2025-09-22 DOI: 10.1016/j.euroneuro.2025.09.007

Yuqing You , Jinyan Guo , Weifeng Yao

引用次数: 0

Response to Commentaries on Article: “Differences in resting-state functional connectivity between depressed bipolar and major depressive disorder patients: A machine learning study” 对文章评论的回应：“抑郁症双相情感障碍和重度抑郁症患者静息状态功能连接的差异：一项机器学习研究”

IF 6.7 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-11-01 Epub Date: 2025-09-22 DOI: 10.1016/j.euroneuro.2025.09.004

Benedetta Vai , Francesco Benedetti

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

European Neuropsychopharmacology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀